Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in HKD (TTM)838.65m
- Net income in HKD-505.83m
- Incorporated2015
- Employees1.11k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 404.97k | -402.17m | 2.74bn | 150.00 | -- | 4.25 | -- | 6,772.28 | -1.12 | -1.12 | 0.0011 | 1.72 | -- | -- | -- | 2,792.90 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.17m | -17.40m | 3.15bn | 275.00 | -- | 1.41 | 886.04 | 5.89 | -0.0295 | -0.0295 | 0.8225 | 3.27 | 0.2159 | -- | 65.75 | 2,070,417.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.81m | -746.44m | 4.13bn | 477.00 | -- | 2.58 | -- | 605.92 | -1.34 | -1.34 | 0.0122 | 2.79 | 0.0027 | -- | 0.302 | 13,198.43 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 274.85m | -231.63m | 4.41bn | 429.00 | -- | 2.53 | -- | 16.04 | -0.2406 | -0.2406 | 0.2855 | 1.81 | 0.1145 | 0.8256 | 13.94 | 631,848.10 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
| Laekna Inc | 0.00 | -317.46m | 5.19bn | 92.00 | -- | 7.14 | -- | -- | -0.8909 | -0.8909 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 220.30m | -78.01m | 5.22bn | 491.00 | -- | 5.31 | 383.59 | 23.68 | -0.0462 | -0.0462 | 0.1323 | 0.5744 | 0.0847 | 1.86 | 1.53 | 513,514.70 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| TYK Medicines Inc | 0.00 | -459.69m | 10.31bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Keymed Biosciences Inc | 87.71m | -798.20m | 11.05bn | 1.12k | -- | 3.90 | -- | 125.98 | -3.05 | -3.05 | 0.3355 | 10.13 | 0.0207 | 0.3115 | 7.74 | 97,782.76 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 970.03m | -387.02m | 13.36bn | 574.00 | -- | 16.21 | -- | 13.78 | -1.34 | -1.34 | 3.33 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,663,856.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| InnoCare Pharma Ltd | 838.65m | -505.83m | 13.67bn | 1.11k | -- | 1.55 | -- | 16.31 | -0.2995 | -0.2995 | 0.4965 | 4.21 | 0.0786 | 0.9875 | 3.19 | 770,111.10 | -4.88 | -13.41 | -6.20 | -15.36 | 85.59 | 85.99 | -62.04 | -172.16 | 3.77 | -- | 0.1667 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Genscript Biotech Corp | 7.86bn | -1.38bn | 22.57bn | 7.28k | -- | 2.38 | -- | 2.87 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,786.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Data as of Nov 22 2024. Currency figures normalised to InnoCare Pharma Ltd's reporting currency: Hong Kong Dollar HKD
